Diffusion weighted imaging (DWI) has an established role in detecting acute brain injury, most notably in the early detection of stroke. The application of cardiac diffusion- weighted MRI (cDWI) is similarly relevant for non-invasive assessment of myocardial injury;however, in vivo cDWI remains a major technical challenge since bulk and pulsatile motion of the beating heart make resolving molecular diffusion much more problematic than it is in the brain. A promising application for cDWI is in heart transplantation for surveillance of allograft rejection. Heart transplant (HT) patients undergo routine monthly endomyocardial biopsies (EMB) in the first year and annual intra-arterial coronary angiography (ICA) to monitor for acute and chronic rejection, respectively. These tests are invasive and carry risks of valve damage, renal failure and cardiac perforation. Additionally, this surveillance practice is resource-demanding, adding to the enormous cost of HT. For over 25,000 Americans living with HT, a non-invasive method of graft surveillance - allowing for safe deferral of costly and invasive tests - is highly desirable. The goal of this project is to develop a robust cDWI technique for clinical use, with initial validation in HT patients for non-invasive surveillance of acute and chronic rejection. We propose to overcome the current limitations of cDWI using a short-axis propeller echo-planar imaging (SAP- EPI) MR sequence. By combining the ultra-fast EPI technique with a novel SAP motion-correction algorithm, the challenge of physiologic motion will be addressed while minimizing image distortion of standard EPI; additionally, this acquisition method is inherently flexible and can be reconstructed for high-resolution and time- resolved cardiac imaging.
Aim 1 is sub-divided into technical (1A) and clinical (1B) goals:
Aim 1 A is focused on cDWI sequence development and retrospective correction of motion- induced cardiac errors and signal loss. SAP motion- correction will be developed to deal with the physiologic motion of the beating heart.
Aim 1 B will explore if cDWI can detect acute myocardial damage in the setting of acute cellular rejection (ACR) in HT patients. cDWI data in HT patients with and without ACR determined by gold standard EMB will be compared.
Aim 2 is also sub-divided into technical (2A) and clinical (2B) goals:
Aim 2 A is focused on an advanced technical development of our cDWI sequence from Aim 1, modified for intravoxel incoherent motion (IVIM) with the goal of developing semi-quantitative perfusion imaging which can be performed without a contrast agent.
Aim 2 B will explore if cDWI IVIM perfusion imaging detects altered blood flow in HT patients with cardiac allograft vasculopathy (CAV). Perfusion fractions will be measured in patients with and without evidence of CAV determined by the gold standard ICA. The end-point of the clinical aims is to validate cDWI in the HT population and achieve a general proof of concept that myocardial characterization with cDWI is an achievable and accurate clinical tool. Our results may provide a threshold of altered diffusion/perfusion with cDWI and IVIM that will predict a positive EMB/ICA result - with safe deferral of costly and invasive tests in HT patients below this threshold. In Summary, this proposal aims at creating a new, clinically feasible cDWI sequence which addresses the unresolved issues of physiologic cardiac motion, which has until now prevented development and clinical use of cDWI for cardiac tissue characterization. Developing a robust cDWI sequence may change the existing management paradigm of HT patients by providing a completely non-invasive and risk-free method of allograft surveillance. Ultimately, we expect that the availability of routine cDWI will unlock the potentially game-changing role which cDWI may also have for non-invasive assessment, of myocardial injury abnormal myocardial perfusion in the future.

Public Health Relevance

Current post heart-transplant surveillance to detect challenges have stalled development and clinical use. acute and chronic graft rejection requires repeated The goal of this project is to develop a clinically life-long invasive testing with endomyocardial biopsy robust cardiac DWI framework, and explore if this and catheter angiography. Cardiac diffusion weighted technique can eliminate or substantially reduce the imaging (cDWI) is a completely non-invasive MR need for routine invasive testing in HT patients. imaging technique which can detect tissue abnormalities on a molecular level, but technical

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL121977-01
Application #
8650639
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Danthi, Narasimhan
Project Start
2014-02-15
Project End
2016-01-31
Budget Start
2014-02-15
Budget End
2015-01-31
Support Year
1
Fiscal Year
2014
Total Cost
$381,188
Indirect Cost
$143,688
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Van, Anh T; Aksoy, Murat; Holdsworth, Samantha J et al. (2015) Slab profile encoding (PEN) for minimizing slab boundary artifact in three-dimensional diffusion-weighted multislab acquisition. Magn Reson Med 73:605-13